| Page 126 | Rogel Cancer Center | University of Michigan

A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors This trial is no longer accepting participants. To get information / assistance in finding a clinical study that is right for you, please call Cancer AnswerLine at 800-865-1125. Read more about A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors	A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers This trial is no longer accepting participants. To get information / assistance on finding a clinical trial that is right for you, please call 800-865-1125. Read more about A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers	A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies This clinical trial is no longer accepting participants. To get information / assistance on finding a trial that is right for you, please call Cancer AnswerLine at 800-865-1125. Read more about A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies	A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 Information about this study has moved. You can now read about it on this page. Read more about A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours This trial is no longer accepting participants. To get information / assistance in finding a clinical trial that is right for you, please call Cancer AnwerLine at 800-865-1125. Read more about A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours	Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma This trial is no longer accepting participants. For information / assistance in finding a trial that is right for you, please call Cancer AnswerLine at 800-865-1125. Read more about Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma	Targeted Agent and Profiling Utilization Registry (TAPUR) Study The information about this trial has moved. You can now read about it on this page. Read more about Targeted Agent and Profiling Utilization Registry (TAPUR) Study	Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab Plus Ipilimumab in Subjects With Virus-Positive and Virus-Negative Solid Tumors This trial is no longer accepting participants. For information / assistance in finding a trial that is right for you, please call Cancer AnswerLine at 800-865-1125. Read more about Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab Plus Ipilimumab in Subjects With Virus-Positive and Virus-Negative Solid Tumors
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements The information about this clinical trial has moved. You can now read about it on this page. Read more about An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1) This trial is no longer accepting participants. For information/assistance in finding a trial that is right for you, please call Cancer AnswerLine at 800-865-1125. Read more about Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)

Pages